The expiration of patents on therapeutic biological products raises major technological and policy questions about potential "generic" equivalents – so-called biosimilar or follow-on biologics. While there may be great opportunities for manufacturers and professionals in the biosimilars field, parallel concerns regarding manufacturing, clinical trials, economics, intellectual property, analytical methods, safety and efficacy arise. T he UW Conference on Biosimilars will provide updates and explore potential solutions to these concern.

Respected faculty from the University of Washington and research and business professionals from local biomedical companies will lead you through the state of biosimilars. Participants at the conclusion of the conference will be able to:

•Explain the current availability and impact of biosimilars in Latin America
•Compare and contrast the intellectual property issues between pioneers and generics
•Analyze the FDA’s current view of biosimilars
•Explain the economics of biosimilars through case examples.
•Determine issues surrounding biosimiliars and clinical trials.

Conference Fees: $465 By February 26, 2010 (Early Bird) $550 After February 26, 2010 (Regular) $310 Current UW Students and Faculty